Evidence map›Paper›PMID 39097409›Full record

ArticleLupus science & medicine2024

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.

Irene Altabás-González, Iñigo Rua-Figueroa, Coral Mouriño, Karen Roberts, Norman Jimenez, Julia Martinez-Barrio, María Galindo, Jaime Calvo Alén, Victor Del Campo Pérez, Esther Uriarte Itzazelaia and 24 more

Abstract readMulticenter Study
In one paragraph

Article in Lupus science & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Irene Altabás-GonzálezRheumatology Department, Vigo University Hospital Group, Vigo, Spain.ORCID 0000-0002-0797-5391
Iñigo Rua-FigueroaRheumatology, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain iruafer@gobiernodecanarias.org.ORCID 0000-0002-7894-1690
Coral MouriñoRheumatology Department, Vigo University Hospital Group, Vigo, Spain.
Karen RobertsRheumatology, Instituto de Investigación, Galicia Sur, External Statistical Advisor, Rosario, Argentina.
Norman JimenezIRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.
Julia Martinez-BarrioHospital General Universitario Gregorio Marañón, Madrid, Spain.
María GalindoServicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.ORCID 0000-0002-7264-2577
Jaime Calvo AlénRheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, Spain.ORCID 0000-0001-9378-8412
Victor Del Campo PérezIRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain.
Esther Uriarte ItzazelaiaDepartment of Rheumatology, Donostia University Hospital Gipuzkoa Building, San Sebastian, Spain.
Eva TomeroRheumatology Department, Hospital Universitario de la Princesa, Madrid, Spain.
Mercedes Freire-GonzálezRheumatology, Academic Hospital Juan Canalejo de La Coruña Cardiology Service, A Coruna, Spain.
Víctor Martínez TaboadaRheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain.
Eva SalgadoRheumatology, Complejo Hospitalario de Orense, Ourense, Spain.
Paloma VelaDepartment of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain.
Antonio Fernandez-NebroRheumatology, Hospital Regional Universitario de Málaga, Malaga, Spain.ORCID 0000-0002-2962-9844
Alejandro OlivéRheumatology Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain.
Javier NarváezRheumatology, Hospital Universitario de Bellvitge, Hospitalet de LLobregat, Spain.
Raúl Menor-AlmagroRheumatology Service, Jerez Hospital, Jerez, Spain.
Gregorio Santos SolerDepartment of Rheumatology, Hospital Villajoyosa, Alicante, Spain.
José Ángel Hernández-BeriainRheumatology, Hospital Insular of Gran Canaria, Gran Canaria, Spain.
Javier ManeroDepartment of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Elena AurrecoecheaRheumatology, Hospital Sierrallana, Torrelavega, Spain.
Oihane Ibarguengoitia-BarrenaRheumatology Department, Hospital Universitario de Basurto, Bilbao, Spain.
Carlos MontillaHospital Universitario de Salamanca, Salamanca, Spain.
Gema BonillaRheumatology, La Paz University Hospital, Madrid, Spain.
Vicenç Torrente-SegarraRheumatology, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despi, Spain.
Ana Paula CachedaDepartment of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain.
María Jesús García-VillanuevaHospital Universitario Ramon y Cajal, Madrid, Spain.
Claudia Moriano-MoralesDepartment of Rheumatology, Hospital de León, León, Spain.
Concepción Fito MantecaDepartment of Rheumatology, Universidad de Navarra-Campus Universitario, Pamplona, Spain.
Nuria Lozano-RivasRheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain.
Cristina BohórquezDepartment of Rheumatology, Hospital Universitario Príncipe de Asturias, Alcala de Henares, Spain.
José M Pego-ReigosaRheumatology Department, Vigo University Hospital Group, Vigo, Spain.ORCID 0000-0003-3461-3537

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort.

methodsMulticentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded.

resultsDuring the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering 'cerebrovascular accident' and 'claudication for 6 months' as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20-25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI.

conclusionsNew damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE.

Indexed as

Cardiovascular SystemLupus Erythematosus, SystemicRegistriesAdultCardiovascular DiseasesDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedRheumatologySeverity of Illness IndexSpainAutoimmune DiseasesCardiovascular DiseasesLupus Erythematosus, Systemic

Identifiers

PMID39097409
PMCPMC11331961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.